Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.

119 HRES 685 IH: Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes. U.S. House of Representatives 2025-09-09 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. IV 119th CONGRESS 1st Session H. RES. 685 IN THE HOUSE OF REPRESENTATIVES September 9, 2025 Mrs. Cammack (for herself, Ms. Kamlager-Dove , Mrs. Kim , Ms. Pettersen , Mrs. Hinson , Ms. Adams , Mrs. Cherfilus-McCormick , and Mr. Landsman ) submitted the following resolution; which was referred to the Committee on Energy and Commerce RESOLUTION Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes. Whereas antiphospholipid syndrome (APS) is a condition in which the immune system of an individual mistakenly produces antibodies that increase the risk of blood clots; Whereas APS can increase the risk of miscarriages, stillbirths, and pregnancy complications; Whereas professional medical associations and guideline-setting bodies do not recommend testing for APS as a standard part of prenatal screening; Whereas professional medical associations and guideline-setting bodies recommend testing for APS only if a woman has an unexplained fetal loss after 10 weeks or 3 or more unexplained embryonic losses (miscarriages); Whereas APS is responsible for about 15 percent of recurrent pregnancy losses; Whereas the total number of miscarriages caused by APS is unknown because it is not tested as part of normal prenatal screening; Whereas APS can be detected by a blood test and treated by blood thinners; and Whereas testing for APS during normal prenatal screening can save babies and reduce grief for women and families: Now, therefore, be it That the House of Representatives— (1) supports testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening; and (2) calls upon professional medical associations and guideline-setting bodies to update their recommendations to include testing for APS as a standard part of prenatal screening.